RDEA119inhibitsMEK1/2andexhibitsanticancerchemotherapeuticactivity.RDEA119iscurrentlyinclinicaltrialsasapotentialtreatmentforavarietyofadvancedcancers.Thiscompoundinhibitsproliferationinthyroidcancercells,includingthosecontainingV600EB-Rafmutations.RDEA119alsoinhibitstumorgrowthinanimalmodelsofmelanoma,coloncancer,andepidermalcarcinoma.
| CasNo. | 923032-37-5 |
|---|---|
| Purity | ≥98% |
| Formula | C19H20F3lN2O5S |
| FormulaWt. | 572.34 |
| IUPACName | N-[3,4-difluoro-2-(2-fluoro-4-iodoanilino)-6-methoxyphenyl]-1-[(2S)-2,3-dihydroxypropyl]cyclopropane-1-sulfonamide |
| Synonym | Refametinib,BAY869766 |
| Appearance | WhitePowder |
| StoreTemp | -20°C |
|---|---|
| ShipTemp | Ambient |
| InfoSheet | R1217InfoSheetPDF |
|---|---|
| Brochures | Ras-Raf-MEK-ERKPathwayBooklet |
WeekesCD,VonHoffDD,AdjeiAA,etal.MulticenterphaseItrialofthemitogen-activatedproteinkinase1/2inhibitorBAY86-9766inpatientswithadvancedcancer.ClinCancerRes.2013Mar1;19(5):1232-43.PMID:23434733.
LiuD,XingJ,TrinkB,etal.BRAFmutation-selectiveinhibitionofthyroidcancercellsbythenovelMEKinhibitorRDEA119andgenetic-potentiatedsynergismwiththemTORinhibitortemsirolimus.IntJCancer.2010Dec15;127(12):2965-73.PMID:21351275.
IversonC,LarsonG,LaiC,etal.RDEA119/BAY869766:apotent,selective,allostericinhibitorofMEK1/2forthetreatmentofcancer.CancerRes.2009Sep1;69(17):6839-47.PMID:19706763.
